Indeed, Taylor Swift and Travis Kelce's walked down the aisle, their whole town came and their mamas cried. She said I do and he did too—just like one of her songs. And after they exchanged vows and ...

Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward ...

PHILADELPHIA (WPVI) -- Skin rashes can be a real nuisance, but they're generally benign. However, there is one time when that incessant itching can be a sign of something more serious. "This tends to ...

Primary cutaneous diffuse large B-cell lymphoma (PC-DLBCL) is a rare subtype of non-Hodgkin lymphoma with nonspecific cutaneous manifestations, leading to frequent misdiagnosis. This case describes an ...

A single infusion of a genetically reprogrammed immune cell therapy produced confirmed cancer-free survival in more than one-third of large B-cell lymphoma patients and nearly half of follicular ...

After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel ...

Anaplastic large cell lymphoma is a rare type of non-Hodgkin lymphoma that primarily affects T cells. While most cases respond well to conventional chemotherapy, achieving long-term survival rates as ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...

Approximately 30%-50% of patients with relapsed or refractory B-cell non-Hodgkin lymphomas have achieved durable remissions with CAR T-cell therapies targeting CD19 over follow-up periods of up to 5 ...

Almost a third of patients with aggressive lymphoma remained cancer free 10 years after treatment with CAR T-cell therapy. The long-term data indicate that CD19-directed CAR T-cell therapy may cure ...